An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001
PHASE2CompletedINTERVENTIONAL
Enrollment
5
Participants
Timeline
Start Date
August 31, 2016
Primary Completion Date
June 30, 2017
Study Completion Date
August 31, 2017
Conditions
Sickle Cell Disease
Interventions
DRUG
GBT440
Oral drug
Trial Locations (1)
SE1 9RT
The BRC Research Facility, Floor 15 The Tower Wing, London
NCT03041909 - An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001 | Biotech Hunter | Biotech Hunter